Doctors Recast Fatty Liver as MASLD, Flagging CKM Syndrome as 3-Organ Metabolic Risk
Updated
Updated · The Indian Express · Jul 9
Doctors Recast Fatty Liver as MASLD, Flagging CKM Syndrome as 3-Organ Metabolic Risk
2 articles · Updated · The Indian Express · Jul 9
Summary
MASLD, PMOS and CKM syndrome reflect a medical shift to treat fatty liver, ovarian and cardio-kidney conditions as linked signs of underlying metabolic dysfunction rather than isolated diseases.
130/80 mmHg blood pressure, prediabetes, high cholesterol, fatty liver and enlarging waistlines are among the early warning signs doctors say often appear years before heart, kidney or diabetic complications.
South Asians can develop insulin resistance and organ fat even at a normal BMI, while inactivity, poor diet, stress, poor sleep and muscle loss after 35 are cited as major drivers.
Regular screening after 35—including HbA1c, lipid, liver and kidney tests—can catch silent damage early, and experts say lifestyle changes plus medication when needed can reduce future cardiovascular and renal risk.
PCOS was just renamed a metabolic disorder. How does this change long-term health management for millions of women?
A 'normal' cholesterol test can be misleading. What is the one blood test that reveals your true heart risk?
Doctors now link common diseases to one root cause. Is your treatment plan missing the real problem?
1.3 Billion Affected: The Global Surge of MASLD and the Shift from NAFLD—Implications for Health Policy, Clinical Practice, and Public Health
Overview
This report highlights the recent global effort to redefine fatty liver disease, moving from the term NAFLD to MASLD to better reflect its metabolic origins and improve research, funding, and patient outcomes. Led by a multi-stakeholder initiative, this change introduces MASLD as the new standard, emphasizing the need for consistent terminology. The report also explores the systemic impact of MASLD, its strong links to cardiovascular and kidney diseases, and the growing global burden. It discusses updated clinical guidelines, the importance of lifestyle changes, emerging therapies, and the need for integrated public health strategies to address policy gaps and improve care worldwide.